Patents by Inventor Christelle Mabilat

Christelle Mabilat has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Adenovirus-mediated intratumoral delivery of an angiogenesis antagonist for the treatment of tumors
    Publication number: 20040265273
    Abstract: The present invention relates to gene therapy for the treatment of tumors. The invention more particularly relates to introduction of a gene encoding an anti-angiogenic factor into cells of a tumor, for example with a defective adenovirus vector, to inhibit growth or metastasis, or both, of the tumor. In a specific embodiment, delivery of a defective adenovirus that expresses the amino terminal fragment of urokinase (ATF) inhibited growth and metastasis of tumors. These effects were correlated with a remarkable inhibition of neovascularization within, and at the immediate vicinity of, the injection site. Delivery of a defective adenovirus vector that expresses kringles 1 to 3 of angiostatin inhibited tumor growth and tumorigenicity, and induced apoptosis of tumor cells. The invention further provides viral vectors for use in the methods of the invention.
    Type: Application
    Filed: October 27, 2003
    Publication date: December 30, 2004
    Inventors: Hong Li, He Lu, Frank Griscelli, Paule Opolon, Claudine Soria, Thierry Ragot, Yves Legrand, Jeannette Soria, Christelle Mabilat, Michel Perricaudet, Patrice Yeh
  • Adenovirus-mediated intratumoral delivery of an angiogenesis antagonist for the treatment of tumors
    Patent number: 6638502
    Abstract: The present invention relates to gene therapy for the treatment of tumors. The invention more particularly relates to introduction of a gene encoding an anti-angiogenic factor into cells of a tumor, for example with a defective adenovirus vector, to inhibit growth or metastasis, or both, of the tumor. In a specific embodiment, delivery of a defective adenovirus that expresses the amino terminal fragment of urokinase (ATF) inhibited growth and metastasis of tumors. These effects were correlated with a remarkable inhibition of neovascularization within, and at the immediate vicinity of, the injection site. Delivery of a defective adenovirus vector that expresses kringles 1 to 3 of angiostatin inhibited tumor growth and tumorigenicity, and induced apoptosis of tumor cells. The invention further provides viral vectors for use in the methods of the invention.
    Type: Grant
    Filed: June 29, 2000
    Date of Patent: October 28, 2003
    Assignee: Gencell SAS
    Inventors: Hong Li, He Lu, Frank Griscelli, Paule Opolon, Claudine Soria, Thierry Ragot, Yves Legrand, Jeannette Soria, Christelle Mabilat, Michel Perricaudet, Patrice Yeh